Blood test could spare lung cancer patients from needless treatments

NCT ID NCT05889247

Recruiting now Disease control Sponsor: Zealand University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether regular blood tests (liquid biopsies) can better monitor treatment in 350 people with advanced non-small cell lung cancer who are receiving immunotherapy. The goal is to see if this approach reduces the number of ineffective treatments and unnecessary side effects, while also being cost-effective. Participants will be randomly assigned to either standard monitoring or monitoring guided by the blood test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

Department of Clinical Oncology
RECRUITING

Hillerød, Region H, Denmark
Department of Clinical Oncology and Palliative Care
RECRUITING

Næstved, Region Sjælland, Denmark
Department of Clinical Oncology and Palliative Care
RECRUITING

Roskilde, Region Sjælland, Denmark
Department of Oncology
NOT_YET_RECRUITING

Aalborg, Denmark
Department of Oncology
NOT_YET_RECRUITING

Vejle, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.